PFE has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
This is the expense the company spent on research and development. Pfizer Inc's research and development for the three months ended in Sep. 2016 was $1,881 Mil. Its research and development for the trailing twelve months (TTM) ended in Sep. 2016 was $7,708 Mil.
This is the expense the company spent on research and development.
Pfizer Inc Research & Development for the trailing twelve months (TTM) ended in Sep. 2016 was 2348 (Dec. 2015 ) + 1731 (Mar. 2016 ) + 1748 (Jun. 2016 ) + 1881 (Sep. 2016 ) = $7,708 Mil.
If competitive advantage is created by a patent or tech advantage, at some point it will disappear.
High R&D usually dictates high SG&A which threatens the competitive advantage.
Pfizer Inc Annual Data
|Research & Development||7,599||8,089||8,578||7,845||9,483||8,681||7,482||6,678||8,393||7,690|
Pfizer Inc Quarterly Data
|Research & Development||1,759||1,802||3,209||1,885||1,734||1,722||2,348||1,731||1,748||1,881|